Nothing Special   »   [go: up one dir, main page]

DK0768312T3 - Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron - Google Patents

Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron

Info

Publication number
DK0768312T3
DK0768312T3 DK96116661T DK96116661T DK0768312T3 DK 0768312 T3 DK0768312 T3 DK 0768312T3 DK 96116661 T DK96116661 T DK 96116661T DK 96116661 T DK96116661 T DK 96116661T DK 0768312 T3 DK0768312 T3 DK 0768312T3
Authority
DK
Denmark
Prior art keywords
derivatives
improve
function
striatal neuron
striatal
Prior art date
Application number
DK96116661T
Other languages
English (en)
Inventor
Michael E Lewis
Nicola Neff
Jill Roberts-Lewis
Chikara Murakata
Hiromitsu Saito
Yuzuru Matsuda
James C Kauer
Marcie A Glicksman
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK0768312T3 publication Critical patent/DK0768312T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96116661T 1992-07-24 1993-07-26 Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron DK0768312T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92010292A 1992-07-24 1992-07-24

Publications (1)

Publication Number Publication Date
DK0768312T3 true DK0768312T3 (da) 2000-12-11

Family

ID=25443161

Family Applications (3)

Application Number Title Priority Date Filing Date
DK99120008T DK1002534T3 (da) 1992-07-24 1993-07-26 Anvendelse af fire K-252a-derivater
DK93917337.3T DK0651754T3 (da) 1992-07-24 1993-07-26 K-252a-derivater
DK96116661T DK0768312T3 (da) 1992-07-24 1993-07-26 Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK99120008T DK1002534T3 (da) 1992-07-24 1993-07-26 Anvendelse af fire K-252a-derivater
DK93917337.3T DK0651754T3 (da) 1992-07-24 1993-07-26 K-252a-derivater

Country Status (17)

Country Link
US (1) US5461146A (da)
EP (4) EP1002534B1 (da)
JP (3) JP3762427B2 (da)
KR (1) KR100276008B1 (da)
AT (3) ATE152111T1 (da)
AU (1) AU675236B2 (da)
BR (1) BR9306789A (da)
CA (1) CA2140924A1 (da)
DE (3) DE69329397T2 (da)
DK (3) DK1002534T3 (da)
ES (3) ES2101331T3 (da)
GR (2) GR3023817T3 (da)
HU (5) HU225341B1 (da)
NO (2) NO305481B1 (da)
NZ (2) NZ286198A (da)
PT (1) PT768312E (da)
WO (1) WO1994002488A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
JP3344586B2 (ja) * 1993-05-28 2002-11-11 セファロン，インコーポレイテッド インドロカルバゾール誘導体を含有する前立腺病理疾患の治療剤
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5541347A (en) * 1993-12-07 1996-07-30 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
ATE181049T1 (de) * 1993-12-07 1999-06-15 Lilly Co Eli Synthese von bisindolylmaleimiden
DE69428025T2 (de) * 1993-12-07 2002-05-29 Eli Lilly And Co., Indianapolis Proteinkinase C-Inhibitoren
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
KR100464907B1 (ko) * 1994-10-26 2005-07-04 세파론, 인코포레이티드 신경계질환치료용단백질키나아제억제제
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
WO1997041854A1 (en) * 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) * 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
EP0912184B1 (en) * 1996-06-25 2002-09-25 Cephalon, Inc. Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US7144997B2 (en) * 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
PL193375B1 (pl) † 1997-08-15 2007-02-28 Cephalon Inc Kompozycja zawierająca inhibitor kinazy tyrozynowej i środek do kastracji chemicznej i jej zastosowanie w terapii i do inhibitowania progresji raka prostaty oraz zastosowanie inhibitora kinazy tyrozynowej i środka do kastracji chemicznej do inhibitowania progresji raka prostaty
EP1044203B1 (en) 1997-12-31 2003-03-12 Cephalon, Inc. 3'-epimeric k-252a derivatives
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
KR100628847B1 (ko) 1998-09-25 2006-09-29 세파론, 인코포레이티드 감각 유모 세포 및 와우 뉴런의 손상의 예방 또는 치료 방법
US6451787B1 (en) * 1998-10-13 2002-09-17 Cephalon, Inc. Remedies for ocular diseases
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
WO2001004090A2 (en) 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
CZ200265A3 (cs) 1999-07-09 2002-07-17 Ortho-Mcneil Pharmaceutical, Inc. Neurotrofní pyrrolidiny a piperidiny
AU2576501A (en) * 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AU2001278084A1 (en) * 2000-07-31 2002-02-13 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
DE10113513A1 (de) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
JP4959918B2 (ja) 2001-10-30 2012-06-27 ノバルティス アーゲー Ｆｌｔ３レセプター・チロシン・キナーゼ活性インヒビターとしてのスタウロスポリン誘導体
US20050130877A1 (en) * 2003-03-14 2005-06-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitors
US6664266B2 (en) * 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
AU2004262927B2 (en) 2003-08-08 2008-05-22 Novartis Ag Combinations comprising staurosporines
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US8076320B2 (en) 2004-02-27 2011-12-13 Cephalon, Inc. Crystalline forms of a pharmaceutical compound
CA2574150C (en) * 2004-07-19 2018-02-27 The Johns Hopkins University Flt3 inhibitors for immune suppression
CN100513850C (zh) * 2005-08-23 2009-07-15 浙江华夏阀门有限公司 三角截面密封套
WO2007022999A1 (en) * 2005-08-25 2007-03-01 Creabilis Therapeutics S.P.A. Polymer conjugates of k-252a and derivatives thereof
AR056517A1 (es) 2005-09-16 2007-10-10 Schering Corp Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
WO2007042286A1 (en) 2005-10-11 2007-04-19 Merck Patent Gmbh Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
EP2147013A4 (en) * 2007-04-16 2012-03-07 Modgene Llc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND FEARING
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
JP2016507493A (ja) 2012-12-21 2016-03-10 スィーケフス ソールラン ホーエフ 神経障害及び疼痛のｅｇｆｒ標的治療
EP3706735A1 (en) * 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
WO2024018245A1 (en) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en) 2023-01-20 2024-07-25 Institut National de la Santé et de la Recherche Médicale Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554402A (en) * 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62102388A (ja) * 1985-10-29 1987-05-12 Toppan Printing Co Ltd Ｉｃカ−ド
JPS62155285A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) * 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
WO1988007045A1 (en) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
AU2322392A (en) * 1991-07-03 1993-02-11 Regeneron Pharmaceuticals, Inc. Method and assay system for neurotrophin activity
DE4133605C2 (de) * 1991-10-10 1994-05-11 Siemens Ag Flexibler Roboterarm
EP0610433A1 (en) * 1991-11-08 1994-08-17 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung

Also Published As

Publication number Publication date
DE69329397T2 (de) 2001-03-15
DK1002534T3 (da) 2006-01-23
HU9500192D0 (en) 1995-03-28
JP2003113184A (ja) 2003-04-18
HUT71239A (en) 1995-11-28
AU4688193A (en) 1994-02-14
NZ286198A (en) 2001-06-29
CA2140924A1 (en) 1994-01-25
EP1512688A1 (en) 2005-03-09
ATE152111T1 (de) 1997-05-15
ES2101331T3 (es) 1997-07-01
DE69329397D1 (de) 2000-10-12
NO990542L (no) 1999-02-05
EP0768312A3 (en) 1997-06-04
ATE304848T1 (de) 2005-10-15
DE69333874D1 (de) 2006-02-02
NO950242D0 (no) 1995-01-23
NO307446B1 (no) 2000-04-10
HU225342B1 (en) 2006-10-28
HU225341B1 (en) 2006-10-28
JP3723533B2 (ja) 2005-12-07
DE69310178T2 (de) 1997-09-25
WO1994002488A1 (en) 1994-02-03
BR9306789A (pt) 1998-12-08
KR950702564A (ko) 1995-07-29
JP2005170955A (ja) 2005-06-30
EP0768312B1 (en) 2000-09-06
EP0768312A2 (en) 1997-04-16
US5461146A (en) 1995-10-24
JP3762427B2 (ja) 2006-04-05
GR3023817T3 (en) 1997-09-30
AU675236B2 (en) 1997-01-30
NO305481B1 (no) 1999-06-07
JPH08501080A (ja) 1996-02-06
NZ254662A (en) 1996-11-26
EP0651754B1 (en) 1997-04-23
NO950242L (no) 1995-03-07
ES2248950T3 (es) 2006-03-16
HU0301601D0 (en) 2003-08-28
KR100276008B1 (ko) 2000-12-15
ATE196142T1 (de) 2000-09-15
HU225297B1 (en) 2006-09-28
HK1028206A1 (en) 2001-02-09
EP1002534A1 (en) 2000-05-24
PT768312E (pt) 2001-03-30
GR3034917T3 (en) 2001-02-28
EP1002534B1 (en) 2005-09-21
DK0651754T3 (da) 1997-10-27
EP0651754A1 (en) 1995-05-10
ES2151629T3 (es) 2001-01-01
DE69310178D1 (de) 1997-05-28
HU0301425D0 (en) 2003-07-28
EP0651754A4 (en) 1995-08-09
NO990542D0 (no) 1999-02-05
DE69333874T2 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
DK0768312T3 (da) Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron
FI102069B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi
KR900009625A (ko) 피리미딘류 및 그의 약리학적으로 허용되는 염류 및 그 용도
NO941968D0 (no) Organiske salter av N,N'-diacetylcystin
ES2093361T3 (es) Tratamiento de enfermedades neurodegenerativas.
FI953899A7 (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
PT97259A (pt) Processo para a estabilizacao de isotiazolonas com fenoxialcanois
ITMI913465A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fuoroetano
FR2713641B1 (fr) Dérivés de l'épi-épibatidine.
FI895977A7 (fi) 3,4-hydroksibentsoyloksipropanoliaminien esilääkeaine
FI892132A7 (fi) 2',3'-didehydro-2',3'-dideoksinukleosidien esilääkkeet
DE69432268D1 (de) Verwendung von aminierten cyclodextrinen zum löslichmachen von als antiepileptika anzuwendenden dibenzazepinderivaten
ITMI912224A1 (it) Impiego di composti adenosinici nel trattamento dell'ischemia
FI933872A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4h)-on-derivat
FI882388A0 (fi) 4-substituerad 10-cyanmetylenpyrrolo /4,3-e/benzoazepin.
FR2697521B1 (fr) Procédé de synthèse du picolinate d'éthyle.
KR920006305U (ko) 유희용 보우트
KR940000244U (ko) 선반의 재치관 협지구
ES1014790Y (es) Libreta infantil de efectos cambiantes.
FI901907A7 (fi) Anordning till barnsaeng.
BR9003246A (pt) Mecanismo de reversao aperfeicoado
ES1021366Y (es) Calzado infantil
SE9200373D0 (sv) Kindstoed till vapenkolv
NO904154D0 (no) Terapeutisk anvendbare tetralinderivater.